← Human Trials & Peer-Reviewed Studies
Benefits of exenatide on obesity and non-alcoholic fatty liver disease with elevated liver enzymes in patients with type 2 diabetes
Plain-language guide to PMID 24823873 (2014): randomized controlled trial study of Exenatide in 60 patients, fatty liver & elevated liver enzymes.
Key Facts
- PMID
- 24823873
- Journal
- Diabetes/metabolism research and reviews
- Year
- 2014
- Study type
- Randomized Controlled Trial
- Authors
- Shao N et al. (6 authors)
- DOI
- 10.1002/dmrr.2561
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Exenatide in the context of fatty liver & elevated liver enzymes.
The purpose of this study was to evaluate the advantages of exenatide treatment on obesity and non-alcoholic fatty liver disease (NAFLD) with elevated liver enzymes in patients with type 2 diabetes (T2D).
Who Took Part
The study group was 60 patients.
By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.
A total of 60 newly diagnosed patients with obesity, NAFLD with elevated liver enzymes and T2D were included in the study.
The patients were randomly divided into two groups.
How the Study Was Run
In design terms this was a randomized study.
Random assignment meant chance, not the researchers, decided who got Exenatide and who got the comparison, which limits bias.
The methods mention a period of 12 weeks.
The exenatide treatment group (n = 30) were treated with exenatide and insulin glargine, and the intensive insulin therapy group (n = 30) were treated with insulin aspart and insulin glargine for 12 weeks.
Selected clinical characteristics were determined, and ultrasonography was performed at both baseline and 12 weeks following treatment.
What Was Measured
The subject headings attached to it are Biomarkers, Body Mass Index, Combined Modality Therapy, Diabetes Mellitus, Type 2, Diet, Diabetic, Exenatide and Exercise.
The authors tagged it with the keywords exenatide (Exe), non-alcoholic fatty liver disease (NAFLD), obesity and type 2 diabetes (T2D).
What This Means in Plain Language
The paper is a randomized study of Exenatide in 60 patients in people with fatty liver & elevated liver enzymes over 12 weeks.
Its findings take up roughly 7 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.
The publication is from 2014 (Diabetes/metabolism research and reviews), a journal based in England.
More context: the Exenatide compound page, Fatty liver & elevated liver enzymes research.
Our Notes on the Compound
Exenatide: A 39-amino-acid GLP-1 receptor agonist first identified in Gila monster venom; sold as Byetta and Bydureon for type 2 diabetes.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.